Supplementary Information

_JMJD3_ exerts oncorepressor activity in acute promyelocytic leukemia by promoting _PU.1_ expression

Authors: Meng-Xi Wang, Shan-He Yu, and Juan Chen

---

Figure S1. Correlation between _JMJD3_ and _PU.1_ in APL. (A-C) Heatmap of the expression of _JMJD3_ and _PU.1_ in the BM mononuclear cells of AML patients from GSE1729 (A), GSE10358 (B), and GSE1159 (C). (D) The analyses of published ChIP-seq data revealed that both _JMJD3_ and _PU.1_
belong to the target genes of PML and RARα.

**Figure S2.** *PU.1* represents the key target of *JMJD3* in APL. Differentially expressed genes (DEGs) are classified as those with fold change >2 or <0.5 (*p* < 0.05). (A) Heatmap of DEGs in parental and JMJD3 KO HL-60. (B) GSEA of parental and JMJD3 KO HL-60. The gene set of *PU.1* targets was used. (C) Verification of the effects of *PU.1* siRNAs in HL-60. Western blot was conducted to determine the effect of knockdown.
Figure S3. JMJD3 exhibited anti-human AML activity in a PU.1-dependent manner. (A) Flow cytometric analyses of Annexin V (A), and CD11B (B) in NB4 transduced with empty vector, JMJD3-expressing vector, or JMJD3-expressing vector plus PU.1 siRNA-1.